When considering both TIL status (presence or absence) and PD-L1 expression status (positive or negative), the tumor type with both TIL presence and PD-L1-positive expression is most likely to respond to PD-1/PD-L1 blockade therapy (20). Here, CD274 is linked to neoplasm.